232 related articles for article (PubMed ID: 22344874)
21. Nanoprobes for hybrid SPECT/MR molecular imaging.
Misri R; Saatchi K; Häfeli UO
Nanomedicine (Lond); 2012 May; 7(5):719-33. PubMed ID: 22630153
[TBL] [Abstract][Full Text] [Related]
22. Nuclear medicine imaging in tuberculosis using commercially available radiopharmaceuticals.
Sathekge M; Maes A; D'Asseler Y; Vorster M; Van de Wiele C
Nucl Med Commun; 2012 Jun; 33(6):581-90. PubMed ID: 22422098
[TBL] [Abstract][Full Text] [Related]
23. [PET/CT: focal lung uptake of 18F-fluorodeoxyglucose on PET but no structural alterations on CT].
Sánchez-Sánchez R; Rodríguez-Fernández A; Ramírez-Navarro A; Gómez-Río M; Ramos-Font C; Llamas-Elvira JM
Rev Esp Med Nucl; 2010; 29(3):131-4. PubMed ID: 20227797
[TBL] [Abstract][Full Text] [Related]
24. Gadoxetate disodium-enhanced magnetic resonance imaging versus contrast-enhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of colorectal liver metastases.
Seo HJ; Kim MJ; Lee JD; Chung WS; Kim YE
Invest Radiol; 2011 Sep; 46(9):548-55. PubMed ID: 21577131
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of neuroendocrine liver metastases: a comparison of dynamic contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography.
Armbruster M; Sourbron S; Haug A; Zech CJ; Ingrisch M; Auernhammer CJ; Nikolaou K; Paprottka PM; Rist C; Reiser MF; Sommer WH
Invest Radiol; 2014 Jan; 49(1):7-14. PubMed ID: 24002080
[TBL] [Abstract][Full Text] [Related]
26. [Whole body positron emission tomography (PET) with (18F)-fluorodeoxyglucose].
Grupo PET de la SEMN
Rev Esp Med Nucl; 2002 Apr; 21(2):128-30. PubMed ID: 11879625
[No Abstract] [Full Text] [Related]
27. SPECT and PET serve as molecular imaging techniques and in vivo biomarkers for brain metastases.
Palumbo B; Buresta T; Nuvoli S; Spanu A; Schillaci O; Fravolini ML; Palumbo I
Int J Mol Sci; 2014 Jun; 15(6):9878-93. PubMed ID: 24897023
[TBL] [Abstract][Full Text] [Related]
28. Comparison of whole-body PET/CT and PET/MRI in breast cancer patients: lesion detection and quantitation of 18F-deoxyglucose uptake in lesions and in normal organ tissues.
Pace L; Nicolai E; Luongo A; Aiello M; Catalano OA; Soricelli A; Salvatore M
Eur J Radiol; 2014 Feb; 83(2):289-96. PubMed ID: 24331845
[TBL] [Abstract][Full Text] [Related]
29. High-grade glioma radiation therapy target volumes and patterns of failure obtained from magnetic resonance imaging and 18F-FDOPA positron emission tomography delineations from multiple observers.
Kosztyla R; Chan EK; Hsu F; Wilson D; Ma R; Cheung A; Zhang S; Moiseenko V; Benard F; Nichol A
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1100-6. PubMed ID: 24161427
[TBL] [Abstract][Full Text] [Related]
30. Injected dose in pediatric PET.
Watson CC
J Nucl Med; 2010 Oct; 51(10):1657; author reply 1657-8. PubMed ID: 20847164
[No Abstract] [Full Text] [Related]
31. Quantifying the effect of IV contrast media on integrated PET/CT: clinical evaluation.
Mawlawi O; Erasmus JJ; Munden RF; Pan T; Knight AE; Macapinlac HA; Podoloff DA; Chasen M
AJR Am J Roentgenol; 2006 Feb; 186(2):308-19. PubMed ID: 16423932
[TBL] [Abstract][Full Text] [Related]
32. Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer.
Lind P; Kohlfürst S
Semin Nucl Med; 2006 Jul; 36(3):194-205. PubMed ID: 16762610
[TBL] [Abstract][Full Text] [Related]
33. Multimodal nanoparticle imaging agents: design and applications.
Burke BP; Cawthorne C; Archibald SJ
Philos Trans A Math Phys Eng Sci; 2017 Nov; 375(2107):. PubMed ID: 29038384
[TBL] [Abstract][Full Text] [Related]
34. Targeted nuclear imaging of breast cancer: status of radiotracer development and clinical applications.
Kong FL; Kim EE; Yang DJ
Cancer Biother Radiopharm; 2012 Mar; 27(2):105-12. PubMed ID: 21877909
[TBL] [Abstract][Full Text] [Related]
35. Exploration of the impact of stereochemistry on the identification of the novel translocator protein PET imaging agent [(18)F]GE-180.
Chau WF; Black AM; Clarke A; Durrant C; Gausemel I; Khan I; Mantzilas D; Oulie I; Rogstad A; Trigg W; Jones PA
Nucl Med Biol; 2015 Sep; 42(9):711-9. PubMed ID: 26072270
[TBL] [Abstract][Full Text] [Related]
36. Nanoparticles for molecular imaging--an overview.
Minchin RF; Martin DJ
Endocrinology; 2010 Feb; 151(2):474-81. PubMed ID: 20016027
[TBL] [Abstract][Full Text] [Related]
37. Comparison of multidetector CT with F-18-FDG-PET and SPECT in the assessment of myocardial viability in patients with myocardial infarction: a preliminary study.
Lee IH; Choe YH; Lee KH; Jeon ES; Choi JH
Eur J Radiol; 2009 Dec; 72(3):401-5. PubMed ID: 18849129
[TBL] [Abstract][Full Text] [Related]
38. Contrast-enhanced FDG-PET/CT vs. SPIO-enhanced MRI vs. FDG-PET vs. CT in patients with liver metastases from colorectal cancer: a prospective study with intraoperative confirmation.
Rappeport ED; Loft A; Berthelsen AK; von der Recke P; Larsen PN; Mogensen AM; Wettergren A; Rasmussen A; Hillingsoe J; Kirkegaard P; Thomsen C
Acta Radiol; 2007 May; 48(4):369-78. PubMed ID: 17453514
[TBL] [Abstract][Full Text] [Related]
39. Conversion of arterial input functions for dual pharmacokinetic modeling using Gd-DTPA/MRI and 18F-FDG/PET.
Poulin E; Lebel R; Croteau E; Blanchette M; Tremblay L; Lecomte R; Bentourkia M; Lepage M
Magn Reson Med; 2013 Mar; 69(3):781-92. PubMed ID: 22570280
[TBL] [Abstract][Full Text] [Related]
40. Radiomics, Radiogenomics, and Next-Generation Molecular Imaging to Augment Diagnosis of Hepatocellular Carcinoma.
Bell M; Turkbey EB; Escorcia FE
Cancer J; 2020; 26(2):108-115. PubMed ID: 32205534
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
